Clinical trial
Effect of PCSK9 Inhibitor on Acute Coronary Syndrome Patients With Multivessel Disease and Relatively Low LDL-C Level in Chinese Population (CHOICE Study)
NCT05043740 is registered in ClinicalTrials.gov with Second Xiangya Hospital of Central South University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Effect of PCSK9 Inhibitor on Acute Coronary Syndrome Patients With Multivessel Disease and Relatively Low LDL-C Level in Chinese Population (CHOICE Study)
- Lead sponsor
- Second Xiangya Hospital of Central South University
- Phase
- Not applicable
- Overall status
- Unknown status
- Start date
- October 31, 2021
- Completion date
- October 1, 2023
- Enrollment
- 1,360 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.